Timsit, Jean-François
Huntington, Jennifer A.
Wunderink, Richard G.
Shime, Nobuaki
Kollef, Marin H.
Kivistik, Ülo
Nováček, Martin
Réa-Neto, Álvaro
Martin-Loeches, Ignacio
Yu, Brian
Jensen, Erin H.
Butterton, Joan R.
Wolf, Dominik J.
Rhee, Elizabeth G.
Bruno, Christopher J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
https://doi.org/10.1186/s13054-021-03694-3
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
https://doi.org/10.1186/s13613-022-01084-8
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
https://doi.org/10.1186/s13054-021-03773-5
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Article History
Received: 26 February 2021
Accepted: 18 July 2021
First Online: 11 August 2021
Declarations
:
: The study was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. All participants, or their legal representatives, had to provide written informed consent in order to be eligible for participation in the study.
: Not applicable.
: J-FT has received institutional research support from MSD. RGW has received institutional research support and consultancy fees from Merck & Co., Inc. NS has received lecture fees and consultancy fees from Pfizer, MSD, and Sumitomo Dainippon Pharma Co. MHK is a consultant for Merck & Co., Inc. and Shionogi and his efforts are supported by the Barnes-Jewish Hospital Foundation. ÜK has received institutional research support from MSD. MN has received institutional research support from MSD. ÁR-N has received institutional research support from MSD. IM-L has received institutional research support from MSD. JAH, BY, CJB, EHJ, JRB, DJW, and EGR are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA.